Skip to content

CytomX

US · CTMX #3678 by market cap Listed 2015
2.03 -0.02 -0.98%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 2.02 -1.46%
After-hours 2.04 +0.65%
Overnight 2.00 -2.44%
3.961.882.032026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on CTMX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bearish
  • Recent price momentum is -42.2% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 20.8% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall D+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth C

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 12.8% Better than 71%
Free cash flow CAGR (3Y) -74.1% Better than 0%
Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Operating margin -29.3% Better than 11%
Net margin -22.8% Better than 12%
Return on equity -35.2% Better than 11%
Return on invested capital -37.9% Better than 8%
Momentum D-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -38.1% Better than 12%
6-month return -46.0% Better than 9%
12-month return (ex latest month) -37.1% Better than 6%
Distance below 52-week high 75.3% Better than 4%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 3.1x Better than 74%
Debt to assets 2.8% Better than 85%
Interest coverage -33.9x Better than 8%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 540.4% Better than 99%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -0.49%
1M -19.12%
3M -38.30%
6M -45.43%
YTD -52.35%
1Y -46.15%
3Y +46.04%
5Y -72.34%

Key statistics

Price & volume

Prev close
2.05
Open
2.02
Day range
1.97 - 2.16
Avg price
2.04
Volume
4.87M
Turnover
9.93M
Amplitude
9.51%
52-week range
1.87 - 8.21

Valuation

P/E
-13.53
P/E (TTM)
-3.98
P/B
1.55
EPS
-0.15
Net profit
-32.70M
Net assets
284.93M

Share structure

Market cap
442.55M
Float cap
366.07M
Shares out
218.00M
Float shares
180.33M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2015-10-08
52-week range 3% of range
1.87 8.21

75.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-2.89M net over the window

Short interest

Shares short
45.25M
As of
2026-10-30

Frequently asked questions

What is the current stock price of CytomX (CTMX)?

CytomX last traded at 2.03. This page shows a periodic quote snapshot. Check the displayed quote time.

What is CytomX's market cap?

About 442.55M.

What is the P/E ratio of CytomX?

The trailing twelve-month P/E is -3.98. The Valuation tab shows it against the stock's own five-year range.

Does CytomX pay a dividend?

CytomX does not currently pay a regular dividend.

Is CytomX a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 13.00, which implies 540.4% upside from the current price. This is not investment advice.

What is CytomX's StockVane Quant Rating?

The StockVane Momentum strategy currently rates CytomX a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 20:02:20 · For reference only, not investment advice and not tailored to your situation.

CytomX discussion 0 comments

Add a comment